Profile picture for Brian Jaros, MD

Brian Jaros, MD

Dr. Brian Jaros is an Assistant Professor of Medicine at Northwestern University Feinberg School of Medicine in Chicago, IL, where he recently completed his rheumatology fellowship training in 2024 and was honored as an American College of Rheumatology Distinguished Fellow. Dr. Jaros's clinical interest is in vasculitis and he is the Associate Director of the Vasculitis Center at Northwestern University. He has authored textbook chapters in vasculitis, moderated panels with the Vasculitis Foundation, and serves as Co-PI for several vasculitis research initiatives in his department. Dr Jaros's other focus is on medical education, and he serves as the Associate Program Director of the Rheumatology Fellowship at Northwestern University. 

Articles By Brian Jaros, MD

FDG,PET,CT

PET Uptake in Large Vessel GCA – Does tocilizumab help?

By Brian Jaros, MD

Giant cell arteritis (GCA) is the most common form of adult vasculitis in the United States and can be subdivided into those with cranial only symptoms, those with large vessel vasculiti/PMR, and those with mixed features.

Read Article
question marks

Psoriatic Arthritis: Which biologic agent is the best first choice?

By Brian Jaros, MD

A growing arsenal of therapeutic targets in psoriatic arthritis (PsA) has enhanced the landscape of treatment in patients with this disease.

Read Article
ANCA, vasculitis, test

Mimics of ANCA-associated vasculitis: How can we tell?

By Brian Jaros, MD

With increased disease awareness and more regular, accessible testing for anti-neutrophil cytoplasmic antibodies (ANCA), ANCA-associated vasculitis (AAV) has become an increasingly recognized clinical entity in rheumatologic practice. 

Read Article
single marble in group

Novel TYK2 inhibitor Zasocitinib

By Brian Jaros, MD

Similar to JAKs, TYK2 is an important mediator of innate and adaptive immune activation. Unlike JAKs, however, TYK2 is thought to play a minimal role in other pathways, such as metabolic and hematopoietic axes. Therefore, it is hypothesized that TYK2-targeted agents could be effective in rheumatic disease, with a potential for less off-target adverse effects. Zasocitinib is a new, oral TYK2 inhibitor generated using artificial intelligence-assisted compound design.

Read Article
light bulb idea

How New Medications are Reframing Imaging Abnormalities in axSpA

By Brian Jaros, MD

Bimekizumab (BKZ), a monoclonal antibody that selectively targets both IL-17A and IL-17F, was evaluated in the BE MOBILE 1 (non-radiographic axSpA) and BE MOBILE 2 (radiographic axSpA) trials and found to yield significant cli

Read Article
Yes No

Playing it Safe with RA? JAK vs. TNF Debate

By Brian Jaros, MD

Reported safety signals, at odds with the efficacy of these medications, have left rheumatology clinicians in a difficult position when considering when during a patient’s treatment course and in which patients, specifically, JAKi should be used. Two abstracts from ACR convergence 2024 further contribute to our understanding of this potential risk profile.

Read Article
×